No­var­tis beefs up its da­ta bank on Cosen­tyx’s durable ef­fect on qual­i­ty of life as well as scalp pso­ri­a­sis

No­var­tis $NVS be­lieves that it still has a long way to go in de­vel­op­ing the block­buster im­munol­o­gy mar­ket that it has on tap for Cosen­tyx. And their cam­paign to con­tin­ue to ex­pand on the $2 bil­lion the phar­ma gi­ant reaped from the drug last year is get­ting a boost to­day with the re­lease of two new rounds of da­ta on the dura­bil­i­ty of the drug in main­tain­ing a bet­ter qual­i­ty of life for pa­tients and it’s ef­fi­ca­cy in treat­ing a par­tic­u­lar­ly net­tle­some form of pso­ri­a­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.